---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-002480"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2023-04-24T23:59:59+00:00"
generated_at: "2026-06-16T19:10:10.372221+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Compass Therapeutics appoints Richard S. Lindahl to Board and Audit Committee chair

## Summary
- Richard S. Lindahl appointed as Class III director effective April 21, 2023; term expires at 2023 annual meeting.
- Also appointed chairman of Audit Committee; qualifies as independent director and audit committee financial expert.
- Compensation: $45,000 cash retainer, $10,000 additional for Audit Committee chair; 50,000 share option award vesting monthly over four years.
- No family relationships or reportable transactions with the Company or its officers.

## SEC filing metadata
- accession: 0001171843-23-002480
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2023-04-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184323002480/0001171843-23-002480-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184323002480/f8k_042423.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-002480
- JSON: https://secwatch.observer/filing/0001171843-23-002480.json
- Plain text: https://secwatch.observer/filing/0001171843-23-002480.txt

## Key facts
- Executive change
  Richard S. Lindahl was appointed as Class III Director at Compass Therapeutics, Inc..
  - Action: appointed
  - Role: Class III Director
  source text: On April 21, 2023, the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”) approved the appointment of a new director to its Board: Richard S. Lindahl, MBA, who is currently the executive vice president, chief financial officer, and treasurer of Emergent BioSolutions, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1738021/000117184323002480/0001171843-23-002480-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.